HOLOGIC INC, 10-Q filed on 1/29/2026
Quarterly Report
v3.25.4
Cover Page - shares
 3 Months Ended
Dec. 27, 2025
Jan. 23, 2026
Cover [Abstract]    
Title of 12(b) Security Common Stock, $0.01 par value  
Document Transition Report false  
Document Quarterly Report true  
Entity Incorporation, State or Country Code DE  
Entity Address, Postal Zip Code 01752  
Entity File Number 1-36214  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 27, 2025  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q1  
Entity Registrant Name HOLOGIC, INC  
Entity Central Index Key 0000859737  
Current Fiscal Year End Date --09-28  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Common Stock, Shares Outstanding   223,244,905
Entity Shell Company false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
City Area Code (508)  
Local Phone Number 263-2900  
Entity Tax Identification Number 04-2902449  
Entity Address, Address Line One 250 Campus Drive,  
Entity Address, City or Town Marlborough,  
Entity Address, State or Province MA  
Trading Symbol HOLX  
Security Exchange Name NASDAQ  
v3.25.4
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Revenues:    
Revenues $ 1,047.8 $ 1,021.8
Costs of revenues:    
Amortization of acquired intangible assets 41.0 46.0
Gross profit 586.4 580.5
Operating expenses:    
Research and development 60.5 60.3
Selling and marketing 154.9 166.1
General and administrative 127.8 115.7
Amortization of acquired intangible assets 2.3 4.7
Restructuring charges 3.9 3.9
Operating expenses 349.4 350.7
Income from operations 237.0 229.8
Interest income 19.7 24.2
Interest expense (27.6) (30.5)
Other income 0.6 24.0
Income before income taxes 229.7 247.5
Provision for income taxes 50.6 46.5
Net income $ 179.1 $ 201.0
Net income per common share:    
Basic (in usd per share) $ 0.80 $ 0.87
Diluted (in usd per share) $ 0.79 $ 0.87
Weighted average number of shares outstanding:    
Basic (in shares) 224,405 230,284
Diluted (in shares) 225,879 232,107
Product    
Revenues:    
Revenues $ 831.4 $ 817.9
Costs of revenues:    
Cost of revenues 321.9 301.1
Service    
Revenues:    
Revenues 216.4 203.9
Costs of revenues:    
Cost of revenues $ 98.5 $ 94.2
v3.25.4
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Statement of Comprehensive Income [Abstract]    
Net income $ 179.1 $ 201.0
Changes in foreign currency translation adjustment 7.0 (54.8)
Gain (loss) recognized on available-for-sale securities, net of tax 0.0 (1.3)
Gain (loss) recognized on interest rate swaps, net of tax (1.0) 4.9
Other comprehensive income (loss) 6.0 (51.2)
Comprehensive income $ 185.1 $ 149.8
v3.25.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Current assets:    
Cash and cash equivalents $ 2,168.0 $ 1,959.5
Short-term investments 196.7 243.2
Accounts receivable, less reserves 584.2 600.8
Inventory 688.5 679.4
Prepaid expenses and other current assets 176.0 152.0
Prepaid income taxes 30.0 33.2
Total current assets 3,843.4 3,668.1
Property, plant and equipment, net 568.3 559.6
Intangible assets, net 547.3 589.1
Goodwill 3,645.2 3,640.6
Other assets 576.5 557.5
Total assets 9,180.7 9,014.9
Current liabilities:    
Current portion of long-term debt 5.8 2.9
Accounts payable 201.1 193.4
Accrued expenses 570.0 577.7
Deferred revenue 170.9 199.7
Finance lease obligations 3.5 3.5
Total current liabilities 951.3 977.2
Long-term debt, net of current portion 2,502.9 2,505.0
Finance lease obligations, net of current portion 8.1 9.0
Deferred income tax liabilities 41.9 43.4
Deferred revenue, net of current portion 12.4 12.4
Other long-term liabilities 419.0 420.0
Stockholders’ equity:    
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued 0.0 0.0
Common stock, $0.01 par value – 750,000 shares authorized; 302,940 and 302,438 shares issued, respectively 3.0 3.0
Additional paid-in-capital 6,357.5 6,345.4
Retained earnings 3,590.6 3,411.5
Treasury stock, at cost – 79,874 and 79,874 shares, respectively (4,611.2) (4,611.2)
Accumulated other comprehensive loss (94.8) (100.8)
Total stockholders’ equity 5,245.1 5,047.9
Total liabilities and stockholders’ equity $ 9,180.7 $ 9,014.9
v3.25.4
Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Thousands
Dec. 27, 2025
Sep. 27, 2025
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 1,623 1,623
Preferred stock, issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 750,000 750,000
Common stock, issued (in shares) 302,940 302,438
Treasury stock (in shares) 79,874 79,874
v3.25.4
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Millions
Total
Accelerated Share Repurchase Agreement
Common Stock
Additional Paid-in Capital
Retained Earnings
AOCI Attributable to Parent [Member]
Treasury Stock
Treasury Stock
Accelerated Share Repurchase Agreement
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ 5,130.0   $ 3.0 $ 6,244.2 $ 2,845.8 $ (111.5) $ (3,851.5)  
Balance (in shares) at Sep. 28, 2024     301,185          
Balance (in shares) at Sep. 28, 2024             69,460  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of stock options (in shares)     118          
Exercise of stock options       6.8        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)     469          
Vesting of restricted stock units, net of shares withheld for employee taxes       (21.7)        
Stock-based compensation expense 30.1     30.1        
Net income (loss) 201.0       201.0      
Other comprehensive income activity           (51.2)    
Repurchase of common stock (in shares)             3,420 [1] 3,332
Repurchase of common stock   $ (250.0)         $ (271.7) [1] $ (250.0)
Balance (in shares) at Dec. 28, 2024     301,772          
Ending balance at Dec. 28, 2024 4,773.3   $ 3.0 6,259.4 3,046.8 (162.7) $ (4,373.2)  
Balance (in shares) at Dec. 28, 2024             76,212  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance 4,773.3   $ 3.0 6,259.4 3,046.8 (162.7) $ (4,373.2)  
Exercise of stock options (in shares)     98          
Exercise of stock options       4.3        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)     22          
Vesting of restricted stock units, net of shares withheld for employee taxes       (0.2)        
Common stock issued under the employee stock purchase plan (in shares)     159          
Common stock issued under the employee stock purchase plan       9.7        
Stock-based compensation expense 28.4     28.4        
Net income (loss) (17.4)       (17.4)      
Other comprehensive income activity           22.6    
Repurchase of common stock (in shares) [1]             2,995  
Repurchase of common stock [1]             $ (202.0)  
Balance (in shares) at Mar. 29, 2025     302,051          
Ending balance at Mar. 29, 2025 4,618.7   $ 3.0 6,301.6 3,029.4 (140.1) $ (4,575.2)  
Balance (in shares) at Mar. 29, 2025             79,207  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance 4,618.7   $ 3.0 6,301.6 3,029.4 (140.1) $ (4,575.2)  
Exercise of stock options (in shares)     37          
Exercise of stock options       1.5        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)     3          
Vesting of restricted stock units, net of shares withheld for employee taxes       (0.1)        
Stock-based compensation expense 13.5     13.5        
Net income (loss) 194.9       194.9      
Other comprehensive income activity           50.0    
Repurchase of common stock (in shares) [1]             667  
Repurchase of common stock [1]             $ (36.0)  
Balance (in shares) at Jun. 28, 2025     302,091          
Ending balance at Jun. 28, 2025 4,842.5   $ 3.0 6,316.5 3,224.3 (90.1) $ (4,611.2)  
Balance (in shares) at Jun. 28, 2025             79,874  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance 4,842.5   $ 3.0 6,316.5 3,224.3 (90.1) $ (4,611.2)  
Exercise of stock options (in shares)     150          
Exercise of stock options       6.0        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)     4          
Vesting of restricted stock units, net of shares withheld for employee taxes       (0.2)        
Common stock issued under the employee stock purchase plan (in shares)     193          
Common stock issued under the employee stock purchase plan       10.8        
Stock-based compensation expense 12.3     12.3        
Net income (loss) 187.2       187.2      
Other comprehensive income activity           (10.7)    
Balance (in shares) at Sep. 27, 2025     302,438          
Ending balance at Sep. 27, 2025 $ 5,047.9   $ 3.0 6,345.4 3,411.5 (100.8) $ (4,611.2)  
Balance (in shares) at Sep. 27, 2025 79,874           79,874  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ 5,047.9   $ 3.0 6,345.4 3,411.5 (100.8) $ (4,611.2)  
Exercise of stock options (in shares)     55          
Exercise of stock options       3.3        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)     447          
Vesting of restricted stock units, net of shares withheld for employee taxes       (18.1)        
Stock-based compensation expense 26.9     26.9        
Net income (loss) 179.1       179.1      
Other comprehensive income activity           6.0    
Balance (in shares) at Dec. 27, 2025     302,940          
Ending balance at Dec. 27, 2025 $ 5,245.1   $ 3.0 6,357.5 3,590.6 (94.8) $ (4,611.2)  
Balance (in shares) at Dec. 27, 2025 79,874           79,874  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ 5,245.1   $ 3.0 $ 6,357.5 $ 3,590.6 $ (94.8) $ (4,611.2)  
[1] Includes excise tax on share repurchases.
v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Sep. 27, 2025
Mar. 29, 2025
Dec. 28, 2024
OPERATING ACTIVITIES        
Net income $ 179.1 $ 187.2 $ (17.4) $ 201.0
Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation 26.3     23.3
Amortization of acquired intangible assets 43.3     50.7
Stock-based compensation expense 26.9     30.1
Deferred income taxes (1.1)     (19.5)
Other adjustments and non-cash items 6.6     (19.1)
Changes in operating assets and liabilities:        
Accounts receivable 18.0     (41.7)
Inventories (8.6)     (36.1)
Prepaid income taxes 3.2     29.2
Prepaid expenses and other assets (25.1)     13.2
Accounts payable 7.8     36.2
Accrued expenses and other liabilities (17.3)     (54.6)
Deferred revenue (29.2)     (23.4)
Net cash provided by operating activities 229.9     189.3
INVESTING ACTIVITIES        
Capital expenditures (14.7)     (16.8)
Increase in equipment under customer usage agreements (20.4)     (14.8)
Strategic investments 24.0     6.0
Purchase of intellectual property 0.0     (15.4)
Maturities of available-for-sale securities 48.0     32.0
Other activity (1.0)     (1.0)
Net cash used in investing activities (12.1)     (22.0)
FINANCING ACTIVITIES        
Repayment of long-term debt 0.0     (9.4)
Repurchases of common stock 0.0     (517.3)
Proceeds under employee stock plans 8.3     12.2
Payment of minimum tax withholdings on net share settlements of equity awards (18.1)     (21.7)
Payments under finance lease obligations (0.9)     (0.8)
Net cash used in financing activities (10.7)     (537.0)
Effect of exchange rate changes on cash and cash equivalents 1.4     (8.4)
Net increase (decrease) in cash and cash equivalents 208.5     (378.1)
Cash and cash equivalents, beginning of period 1,959.5   $ 1,782.1 2,160.2
Cash and cash equivalents, end of period $ 2,168.0 $ 1,959.5   $ 1,782.1
v3.25.4
Basis of Presentation
 3 Months Ended
Dec. 27, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The unaudited consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 27, 2025 included in the Company’s annual report on Form 10-K filed with the SEC on November 18, 2025. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.

The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 27, 2025 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 26, 2026.

Proposed Merger

On October 21, 2025, the Company entered into a definitive agreement (“Merger Agreement”) to be acquired by funds managed by Blackstone Inc. (“Blackstone”) and TPG Capital (“TPG”) in a transaction valued at up to $79.00 per share. Under the terms of the agreement, Blackstone and TPG will acquire all outstanding Hologic shares for $76.00 per share in cash, without interest, plus a non-tradable contingent value right (“CVR”) to receive up to $3.00 per share in cash, for total potential consideration of up to $79.00 per share in cash. The non-tradable CVR will be issued to Hologic stockholders at closing and paid, in whole or in part, following achievement of certain global revenue metrics for Hologic’s Breast Health business in fiscal years 2026 and 2027.

The transaction is expected to close in the first half of calendar year 2026, subject to the approval of Hologic’s stockholders, the receipt of required regulatory approvals and the satisfaction of certain other customary closing conditions. Upon completion of the transaction, Hologic’s common stock will be delisted from the Nasdaq stock market and deregistered under the Securities Exchange Act of 1934, as amended.

Subsequent Events Consideration

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three months ended December 27, 2025.

On January 7, 2026, the Company executed a settlement agreement to resolve the BioZorb litigation with no admission of liability by the Company. The settlement amount is fully covered by insurance, and the Company expects it will bear no financial liability related to the settlement agreement. In addition, in connection with the potential merger with Blackstone and TPG and the Company filing a preliminary proxy statement on December 12, 2025 and a definitive proxy statement on December 23, 2025, on January 14, 2026 and January 15, 2026 purported stockholders of the Company filed a class action lawsuit and individual actions against the Company and the members of the Company’s board of directors. See footnote 10 for additional information.
v3.25.4
Leases
 3 Months Ended
Dec. 27, 2025
Leases [Abstract]  
Leases Leases
Lessor Activity - Leases where Hologic is the Lessor
Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company’s consolidated revenue for all periods presented.
Leases Leases
Lessor Activity - Leases where Hologic is the Lessor
Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company’s consolidated revenue for all periods presented.
v3.25.4
Fair Value Measurements
 3 Months Ended
Dec. 27, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements
Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The Company has investments in money market funds and United States Treasury securities that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents, and Short term investments on the Consolidated Balance Sheets, which is determined based on maturities at the time of purchase and re-evaluated at each balance sheet date.

The Company also has investments in derivative instruments comprised of an interest rate swap and forward foreign currency contracts. These instruments were valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 9 for further discussion and information on derivative contracts. In addition, the Company has a contingent consideration liability that is recorded at fair value, which is based on Level 3 inputs.

The following table summarizes certain fair value information at December 27, 2025 and September 27, 2025 for investment assets and other liabilities measured at fair value on a recurring basis, as well as the carrying amount of certain investments.
  Fair Value at Reporting Date Using
 
Fair Value
Quoted Prices in
Active Market for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs (Level 2)		Significant
Unobservable
Inputs (Level 3)
December 27, 2025
Assets:
Money market mutual funds
$886.7 $886.7 $— $— 
U.S. Treasury securities
196.7 196.7 — — 
Interest rate swap
1.9 — 1.9 — 
Forward foreign currency contracts1.2 — 1.2 — 
Total$1,086.5 $1,083.4 $3.1 $— 
Liabilities:
Forward foreign currency contracts5.4 — 5.4 — 
Total$5.4 $— $5.4 $— 
September 27, 2025
Assets:
Money market mutual funds
$740.2 $740.2 $— $— 
U.S. Treasury securities
332.8 332.8 — — 
Interest rate swap
3.2 — 3.2 — 
Forward foreign currency contracts1.6 — 1.6 — 
Total$1,077.8 $1,073.0 $4.8 $— 
Liabilities:
Forward foreign currency contracts$6.1 $— $6.1 $— 
Total$6.1 $— $6.1 $— 


Assets Measured and Recorded at Fair Value on a Nonrecurring Basis

The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments property, plant and equipment, intangible assets and goodwill. There were no remeasurements in the three months ended December 27, 2025 and December 28, 2024.

Disclosure of Fair Value of Financial Instruments

The Company’s financial instruments mainly consist of cash and cash equivalents, United States Treasury securities, accounts receivable, equity investments, an interest rate swap, forward foreign currency contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s United States Treasury securities, interest rate swap, forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value.

The Company’s cash and cash equivalents and short investments were as follows:

December 27, 2025
ValuationBalance Sheet Classification
in millionsCostUnrealized GainsUnrealized LossesFair ValueCash and cash equivalentsInvestments
Cash
$1,281.3 $— $— $1,281.3 $1,281.3 $— 
Money market mutual funds
886.7 — — 886.7 886.7 — 
U.S. Treasury debt securities
196.6 0.1 — 196.7 — 196.7 
Total
$2,364.6 $0.1 $— $2,364.7 $2,168.0 $196.7 
September 27, 2025
ValuationBalance Sheet Classification
in millionsCostUnrealized GainsUnrealized LossesFair ValueCash and cash equivalentsInvestments
Cash
$1,129.7 $— $— $1,129.7 $1,129.7 $— 
Money market mutual funds
740.2 — — 740.2 740.2 — 
U.S. Treasury debt securities
332.7 0.1 — 332.8 89.6 243.2 
Total
$2,202.6 $0.1 $— $2,202.7 $1,959.5 $243.2 

The Company classifies its investments in debt securities as available-for-sale and records them at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss), which was immaterial for the three months ended December 27, 2025. The Company periodically assesses these securities for potential impairment losses and credit losses. The amount of credit losses, if any, will be determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. There were no impairments and credit losses related to available-for-sale securities for the three months ended December 27, 2025 and December 28, 2024.

The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three months ended December 27, 2025 and December 28, 2024. There were no sales prior to maturity of available-for-sale securities during the three months ended December 27, 2025.

The fair value of the available-for-sale securities by contractual maturity as of December 27, 2025 and September 27, 2025 were as follows:

December 27, 2025September 27, 2025
in millions
Fair Value
Fair Value
Due in three months or less
$— $89.6 
Due after three months through one year
196.7 243.2 
Due after one year through five years
— — 
Total available-for-sale securities
$196.7 $332.8 

Amounts outstanding under the Company’s 2025 Credit Agreement of $1.17 billion aggregate principal as of December 27, 2025 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) and 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) had fair values of $400.0 million and $938.7 million, respectively, as of December 27, 2025 based on their trading prices, representing a Level 1 measurement. Refer to Note 7 for the carrying amounts of the various components of the Company’s debt.
v3.25.4
Business Combinations
 3 Months Ended
Dec. 27, 2025
Business Combination [Abstract]  
Business Combinations Business Combinations
Fiscal 2025 Acquisitions

Gynesonics

On January 2, 2025, the Company completed the acquisition of Gynesonics, Inc. (“Gynesonics”) for a purchase price of $340.7 million. Gynesonics, located in Redwood City, California, develops and sells a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Gynesonics’ results of operations are reported in the Company’s GYN Surgical reportable segment from the date of acquisition. In connection with the transaction, the Company recorded a charge of $22.4 million, of which $1.6 million was included in costs of product revenues and $20.8 million was included in operating expenses, in the second quarter of fiscal 2025 for the acceleration of Gynesonics unvested stock options for which the original terms of such awards did not provide for acceleration upon a change-in-control.

The purchase price was allocated to Gynesonics’ tangible and identifiable intangible assets and liabilities based on their estimated fair values as of January 2, 2025, as set forth below.
Cash$19.2 
Accounts receivable4.5 
Inventory7.2 
Other assets6.7 
Accounts payable and accrued expenses(21.1)
Identifiable intangible assets:
Developed technology140.8 
Trade names4.0 
Customer relationship1.3 
Deferred income taxes, net(14.1)
Goodwill192.2 
Purchase Price$340.7 

In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Gynesonics’ business. During the first quarter of 2026, the Company adjusted the value of deferred tax assets for acquired net operating losses by $1.2 million with an offset to goodwill.

As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, trade names, and customer relationships. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 12.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital.

The developed technology assets are comprised of know-how, patents and technologies embedded in Gynesonics’ products and relate to currently marketed products. The developed technology assets comprise the primary products under the Sonata technology platform.

The estimate of the weighted average life for the developed technology assets was 13 years, customer relationships was 13 years and trade name assets was 13 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Gynesonics acquisition. These expected benefits include expanding the Company’s surgical portfolio and utilizing GYN Surgical’s sales and regulatory expertise to drive adoption of the products and revenue growth. None of the goodwill is expected to be deductible for income tax purposes.
v3.25.4
Strategic Investments
 3 Months Ended
Dec. 27, 2025
Equity Method Investments and Joint Ventures [Abstract]  
Strategic Investments Strategic Investments
Maverix Medical

On November 13, 2023, the Company entered into an agreement with KKR Comet, LLC, an affiliate of KKR & Co. Inc. (“KKR Comet”), to form a legal entity to develop and acquire innovative technologies and commercial operations within the lung cancer space. The new entity, named Maverix Medical LLC (“Maverix”), is managed by Ajax Health. As part of this strategic investment, the Company contributed $24.5 million in return for 45% ownership in the Class A Common units of Maverix, and both the Company and KKR Comet committed to make additional capital contributions in proportion to the ownership percentages upon meeting certain objectives and as approved by the Maverix board. In accordance with ASC 810, Consolidation, and ASC 323, Investments - Equity Method and Joint Ventures, the Company determined that Maverix is a variable interest entity (“VIE”) however the Company is not the primary beneficiary but does have significant influence. Therefore, this investment is being accounted for under the equity method, which requires the Company to record its proportional share of the investee’s net income (loss). This investment is recorded within Other assets in the Consolidated Balance Sheets and the net investment as of December 27, 2025 was $27.2 million, and the Company’s proportionate share of Maverix’s net loss for the three months ended December 27, 2025 and December 28, 2024 was $2.8 million and $1.5 million, respectively.
During the first quarter of fiscal 2026, the Company received a capital call notice for 13.3% of total committed capital for a total amount of $9.0 million, which was paid in December 2025. During the first quarter of fiscal 2025, the Company received a capital call notice for 13.3% of total committed capital for a total amount of $9.0 million, which was paid in January 2025. The Company’s ownership interest did not change from either capital call.

Other

The Company holds other non-marketable equity securities as part of its strategic investments portfolio. Other non-marketable equity securities are measured at cost, less any impairment, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. In addition, these investments are assessed for indicators of impairment, including adverse changes in technological milestones and financial conditions of the investee. Changes in fair value of these strategic investments are recorded in other income (expense), net in the Consolidated Statements of Income. No such changes to fair value or impairments were recorded during the three months ended December 27, 2025 and December 28, 2024. At December 27, 2025 and September 27, 2025, the Company’s investments in equity securities without readily determinable fair values totaled $68.1 million and $53.1 million, respectively, and were included in Other assets on the Consolidated Balance Sheets.
v3.25.4
Borrowings and Credit Arrangements
 3 Months Ended
Dec. 27, 2025
Debt Disclosure [Abstract]  
Borrowings and Credit Arrangements Borrowings and Credit Arrangements
The Company’s borrowings consisted of the following: 

December 27,
2025		September 27,
2025
Current debt obligations, net of debt discount and deferred issuance costs:
Term Loan
$5.8 $2.9 
Total current debt obligations$5.8 $2.9 
Long-term debt obligations, net of debt discount and issuance costs:
Term Loan$1,161.0 $1,163.8 
2028 Senior Notes398.5 398.3 
2029 Senior Notes943.4 942.9 
Total long-term debt obligations$2,502.9 $2,505.0 
Total debt obligations$2,508.7 $2,507.9 

2025 Credit Agreement

On July 15, 2025, the Company, together with certain of its subsidiaries, refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Leader and L/C Issuer, and certain other lenders (the “2021 Credit Agreement”) by entering into a Refinancing Amendment No. 4 (the “2025 Credit Agreement”). The 2025 Credit agreement provided a $1.169 billion secured term loan (“2025 Term Loan”) with a stated maturity date of July 15, 2030, and a $1.25 billion secured revolving credit facility (the “2025 Revolver”). As of December 27, 2025, the principal amount outstanding was $1.169 billion, and the interest rate was 4.83% per annum. No amounts were outstanding under the 2025 Revolver, and the full amount was available to be borrowed by the Company.

The 2025 Credit Agreement contains two financial covenants: a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter on a latest twelve-month basis. The terms and calculations thereof are defined in further detail in the 2025 Credit Agreement. As of December 27, 2025, the Company was in compliance with these covenants.

Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2025 Credit Agreement and the 2021 Credit Agreement were as follows: 
Three Months Ended
December 27, 2025December 28, 2024
Interest expense$15.8 $18.9 
Weighted average interest rate5.00 %5.66 %
Interest rate at end of period4.83 %5.44 %

The Company has an outstanding interest rate swap agreement, which fixed the SOFR component of the variable interest rate on a portion of the aggregate principal under the 2025 Term Loan and the 2021 Term Loan. Under this interest rate swap agreement, the Company received $1.3 million and $1.6 million during the three months ended December 27, 2025 and December 28, 2024, respectively. These amounts were recorded as a reduction to interest expense in the Statements of Income. See Note 9 for additional information.

2028 Senior Notes
    
As of December 27, 2025, the Company had 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) outstanding in the aggregate principal balance of $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 1, 2028.

2029 Senior Notes

As of December 27, 2025, the Company had 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) outstanding in the aggregate principal balance of $950 million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 15, 2029.

Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:

Three Months Ended
Interest RateDecember 27, 2025December 28, 2024
2028 Senior Notes4.625 %$4.8 $4.8 
2029 Senior Notes3.250 %8.2 8.2 
Total$13.0 $13.0 
v3.25.4
Trade Receivables and Allowance for Credit Losses
 3 Months Ended
Dec. 27, 2025
Receivables [Abstract]  
Trade Receivables and Allowance for Credit Losses Trade Receivables and Allowance for Credit Losses
The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity from new macroeconomic events, such as pandemics and inflation, must be taken into consideration. To date, the Company has not experienced significant customer payment defaults or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis.

The following is a rollforward of the allowance for credit losses as of December 27, 2025 compared to December 28, 2024:
Balance at
Beginning
of Period
Credit Loss (Gain)
Write-offs,
Payments and Foreign Exchange		Balance at
End of
Period
Three Months Ended:
December 27, 2025$38.2 $2.3 $(0.6)$39.9 
December 28, 2024$41.4 $(0.3)$(1.0)$40.1 
v3.25.4
Derivatives
 3 Months Ended
Dec. 27, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives Derivatives
Interest Rate Swaps - Cash Flow Hedge

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (“AOCI”) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings.

On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024 (the first quarter of fiscal 2025), and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps was $500 million, and the first interest rate swap fixed the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps were designed to mirror the terms of the Company’s SOFR-based borrowings under the 2025 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $500 million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of the remaining interest rate swap was an asset position of $1.9 million as of December 27, 2025.

Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts

The Company enters into forward foreign currency exchange contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company’s cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the U.K. Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The Company uses forward contracts as part of its foreign currency hedging strategy to manage the risk associated with fluctuations in foreign currency exchange rates. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts. As of December 27, 2025, the notional amount was $251.3 million. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net.

Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three months ended December 27, 2025 and December 28, 2024, respectively, were as follows:

Three Months Ended
December 27, 2025December 28, 2024
Amount of realized gain (loss) recognized in income
Forward foreign currency contracts$(0.2)$0.3 
$(0.2)$0.3 
Amount of unrealized gain (loss) recognized in income
Forward foreign currency contracts$0.2 $22.4 
Foreign currency option contracts— (0.4)
$0.2 $22.0 
Amount of gain (loss) recognized in income
Total$— $22.3 
Financial Instrument Presentation

The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of December 27, 2025:

Balance Sheet LocationDecember 27, 2025September 27, 2025
Assets:
Derivative instruments designated as a cash flow hedge:
Interest rate swap contract
Prepaid expenses and other current assets$1.9 $3.2 
$1.9 $3.2 
Derivatives not designated as hedging instruments:
Forward foreign currency contractsPrepaid expenses and other current assets$1.2 $1.6 
$1.2 $1.6 
Liabilities:
Derivatives not designated as hedging instruments:
Forward foreign currency contractsAccrued expenses$5.4 $6.1 

The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods:

Three Months Ended
December 27, 2025December 28, 2024
Amount of gain (loss) recognized in other comprehensive income, net of taxes:
Interest rate swap
$(1.0)$4.9 
Total$(1.0)$4.9 
v3.25.4
Commitments and Contingencies
 3 Months Ended
Dec. 27, 2025
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
(10) Commitments and Contingencies

Litigation and Related Matters

As previously disclosed by the Company, including in its most recent Annual Report on Form 10-K, on November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a group of plaintiffs who claimed they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints alleged that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and made various additional claims related to the design, manufacture and marketing of the device. Complaints were filed on behalf of approximately 200 plaintiffs, one pending in Massachusetts state court and the remainder in U.S. District Court for the District of Massachusetts. In November 2025, the parties reached an agreement in principle, which was disclosed to the court and later documented in a formal settlement agreement executed on January 7, 2026, to resolve the BioZorb litigation with no admission of liability by the Company. The settlement amount is fully covered by insurance, and the Company expects it will bear no financial liability related to the settlement agreement. The settlement agreement is subject to certain contingencies, including a participation threshold (analogous to a class action opt out threshold), and if all conditions are satisfied, the agreement will result in the dismissal with prejudice of the substantial majority of BioZorb cases.
    
In connection with the potential merger with Blackstone and TPG (the “Merger”), the Company filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement (the “Preliminary Proxy Statement”) on December 12, 2025 and a definitive proxy statement (the “Definitive Proxy Statement”) on December 23, 2025. Purported stockholders of the Company have filed a class action lawsuit and individual actions against the Company and the members of the Company’s board of directors, captioned as follows: Southfield Fire & Police Retirement System v. Hologic, Inc. et al., Case No. 2026-0060-BWD (Del. Ch. January 14, 2026); Smith v. Hologic, Inc., et al., No. 650252/2026 (filed on January 14, 2026), and Thomas v. Hologic, Inc., et al., No. 650272/2026 (filed on January 15, 2026) (the “Complaints”). The Complaints generally allege, among other things, that the Definitive Proxy Statement omits certain purportedly material information regarding the Merger in breach of the directors’ fiduciary duties or in violation of New York state law. The Complaints seek, among other things, to enjoin the stockholder vote on the Merger unless and until the purportedly material information is disclosed. Additionally, beginning on December 15, 2025, the Company has received demand letters (collectively with the Complaint, the “Matters”) from purported stockholders of the Company, alleging that, among other things, the Preliminary Proxy Statement and the Definitive Proxy Statement contain certain disclosure deficiencies and/or incomplete information regarding the Merger. Although the outcome of, or estimate of the possible loss or range of loss from, these Matters cannot be predicted, the Company believes that the allegations contained in these Matters are without merit. Additional complaints and/or demand letters arising out of the Merger may also be filed or received in the future.
The Company is a party to various other legal proceedings, claims, governmental and/or regulatory inspections, inquiries and investigations arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings, claims, inspections, inquiries or investigations pending against it, the ultimate resolution of which are reasonably likely based upon management’s assessment, to have a material adverse effect on its financial condition or results of operations. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these matters. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies (ASC 450). Legal costs are expensed as incurred.
v3.25.4
Net Income Per Share
 3 Months Ended
Dec. 27, 2025
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
A reconciliation of basic and diluted share amounts is as follows:

 Three Months Ended
 December 27,
2025		December 28,
2024
Basic weighted average common shares outstanding224,405 230,284 
Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units1,474 1,823 
Diluted weighted average common shares outstanding225,879 232,107 
Weighted-average anti-dilutive shares related to:
Outstanding stock options and restricted stock units1,449 829 
v3.25.4
Stock-Based Compensation
 3 Months Ended
Dec. 27, 2025
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income:

 Three Months Ended
 December 27,
2025		December 28,
2024
Cost of revenues$3.7 $3.5 
Research and development1.8 2.5 
Selling and marketing4.1 3.7 
General and administrative17.3 20.4 
$26.9 $30.1 

Pursuant to the Merger Agreement, the Company did not grant any stock options for fiscal 2026. The Company granted options to purchase 0.5 million shares of the Company’s common stock during the three months ended December 28, 2024 with a weighted-average exercise price of $79.38. There were 4.2 million options outstanding at December 27, 2025 with a weighted-average exercise price of $58.31.

The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:

 Three Months Ended
 
December 27,
2025 (1)
December 28,
2024
Risk-free interest rate— %4.2 %
Expected volatility— %32.5 %
Expected life (in years)— 4.8
Dividend yield— — 
Weighted average fair value of options granted$— $26.74 
(1) No stock option awards were granted in the first quarter of fiscal 2026

The Company granted 1.1 million and 0.8 million restricted stock units (“RSUs”) during the three months ended December 27, 2025 and December 28, 2024, respectively, with weighted-average grant date fair values of $74.28 and $79.88 per unit, respectively. Pursuant to the Merger Agreement, the Company did not grant any performance stock awards for fiscal 2026. The Company granted 0.1 million performance stock units (“PSUs”) during the three months ended December 28, 2024 to members of its senior management team, which had a weighted-average grant date fair value of $79.39 per unit. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period, provided that the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million of free cash flow performance stock units (“FCF PSUs”) based on a three-year cumulative free cash flow measure to members of its senior management team, which had a grant date fair value of $79.39 per unit during the three months ended December 28, 2024. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of the three-year measurement period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the probable number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million market stock units (“MSUs”) to members of its senior management team during the three months ended December 28, 2024. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $87.41 per share using the Monte Carlo simulation model in fiscal 2025. The MSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. At December 27, 2025, there was 2.1 million in aggregate unvested RSUs, PSUs, FCF PSUs and MSUs outstanding.
At December 27, 2025, there was $8.0 million and $98.6 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.3 and 2.0 years, respectively.

As a result of the Merger Agreement, at closing of the transaction all outstanding restricted stock units, including PSUs and MSUs, granted by the Company prior to the date of executing the Merger Agreement of October 21, 2025 will be cancelled and converted into the right to receive the merger consideration in respect of each share. At the closing, each Company stock option that is outstanding and unvested will vest in full and will be cancelled and converted into the right to receive the merger consideration less the exercise price.
v3.25.4
Other Balance Sheet Information
 3 Months Ended
Dec. 27, 2025
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Information Other Balance Sheet Information
December 27,
2025		September 27,
2025
Inventories
Raw materials$282.0 $247.8 
Work-in-process62.9 68.4 
Finished goods343.6 363.2 
$688.5 $679.4 
Property, plant and equipment
Equipment$391.1 $383.8 
Equipment under customer usage agreements596.5 586.8 
Building and improvements261.1 256.1 
Leasehold improvements49.4 49.1 
Land40.9 40.9 
Furniture and fixtures26.4 26.5 
Finance lease right-of-use asset
9.2 9.2 
$1,374.6 $1,352.4 
Less – accumulated depreciation and amortization(806.3)(792.8)
$568.3 $559.6 
v3.25.4
Business Segments and Geographic Information
 3 Months Ended
Dec. 27, 2025
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic Information
The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s reportable segments have been identified based on the types of products manufactured and the end markets to which the products are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable products and supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company’s chief executive officer is the chief operating decision maker (“CODM”). The Company measures and evaluates its reportable segments based on segment revenues and segment operating income (loss), which includes cost of revenues and operating expenses. The Company allocates the cost of corporate functions, including depreciation expense, to its segments at predetermined rates. The Company excludes from segment expenses and segment operating income certain transactions and expenses that the CODM considers to not be representative of core operating performance, such as amounts related to intangible asset amortization expense, goodwill and intangible asset impairment charges, transaction and integration expenses for acquisitions and other acquisition related charges, restructuring, consolidation and divestiture charges, legal settlements, and other one-time or unusual items.

The CODM uses segment revenues and segment operating income (loss) primarily in the budget, forecasting and quarterly business review processes. During these evaluations, the CODM analyzes budget and forecast versus actual results, which are used to assess the performance of reportable segments and to allocate resources across reportable segments. The table below reconciles segment revenues to segment operating income (loss) with the expense categories presented reflecting the expenses that the Company has determined to be significant segment expenses. Significant segment expenses are the expense categories that are regularly provided to the CODM for decision making.
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company has presented all other identifiable assets as corporate assets.

Three Months Ended December 27, 2025
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthConsolidated
Total revenues$464.4 $375.9 $180.8 $26.7 $1,047.8 
Segment expenses:
Cost of revenues173.9 157.3 67.6 18.8 417.6 
Research and development26.8 24.0 8.4 0.6 59.8 
Sales and marketing56.5 51.1 44.4 1.9 153.9 
General and administrative49.7 40.7 19.9 2.6 112.9 
Segment income from operations$157.5 $102.8 $40.5 $2.8 $303.6 
Unallocated amounts:
Cost of revenue adjustments(1)
2.7 
Amortization of acquired intangible assets43.3 
Restructuring, integration, acquisition-related charges and legal settlements20.6 
Income from operations$237.0 
Interest expense, net(7.9)
Foreign currency and other non-operating income, net0.6 
Income before income taxes$229.7 
(1) Primarily related to costs associated with the shutdown of the Manchester, England manufacturing location, primarily manufacturing period costs and retention benefits related to the merger.
Three Months Ended December 27, 2025
DiagnosticsBreast HealthGYN SurgicalSkeletal Health
Corporate
Consolidated
Depreciation and amortization
$46.2 $12.9 $10.3 $0.2 $— $69.6 
Capital expenditures
23.7 5.6 4.9 — 0.9 35.1 
Identifiable assets
2,232.6 1,526.7 1,636.8 37.7 3,746.9 9,180.7 
Three Months Ended December 28, 2024
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthConsolidated
Total revenues$470.6 $369.1 $166.3 $15.8 $1,021.8 
Segment expenses:
Cost of revenues173.8 160.3 44.8 13.1 392.0 
Research and development32.1 21.0 6.5 0.6 60.2 
Sales and marketing59.6 54.8 39.4 3.0 156.8 
General and administrative49.6 43.3 17.0 2.2 112.1 
Segment income (loss) from operations$155.5 $89.7 $58.6 $(3.1)$300.7 
Unallocated amounts:
Cost of revenue adjustments(1)
3.2 
Amortization of acquired intangible assets50.7 
Restructuring, integration and acquisition-related charges17.0 
Income from operations$229.8 
Interest expense, net(6.3)
Foreign currency and other non-operating income, net24.0 
Income before income taxes$247.5 
(1) Related to the fair value write-up of inventory sold related to the Endomagnetics acquisition.
Three Months Ended December 28, 2024
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthCorporateConsolidated
Depreciation and amortization
$48.6 $13.2 $12.0 $0.2 $— $74.0 
Capital expenditures
17.8 8.9 3.7 — 1.2 31.6 
Year Ended September 27, 2025
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthCorporateConsolidated
Identifiable assets
$2,244.0 $1,531.3 $1,644.9 $31.2 $3,563.5 $9,014.9 

The Company had no customers that represented greater than 10% of consolidated revenues during the three months ended December 27, 2025 and December 28, 2024.

The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.

Revenues by geography as a percentage of total revenues were as follows:
 
 Three Months Ended
 December 27,
2025		December 28,
2024
United States73.8 %74.2 %
Europe15.4 %14.6 %
Asia-Pacific5.4 %5.9 %
Rest of World5.4 %5.3 %
100.0 %100.0 %
v3.25.4
Income Taxes
 3 Months Ended
Dec. 27, 2025
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
In accordance with ASC 740, Income Taxes, each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.

For the three months ended December 27, 2025, the Company recorded income tax expense of $50.6 million resulting in an effective tax rate of 22.0%. The effective tax rate for the three months ended December 27, 2025 was higher than the U.S. statutory tax rate primarily due to U.S. tax on foreign earnings and income tax reserves, partially offset by the U.S. deduction for foreign derived intangible income, income earned by the Company’s international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits.

For the three months ended December 28, 2024, the Company recorded income tax expense of $46.5 million resulting in an effective tax rate of 18.8%. The effective tax rate for the three months ended December 28, 2024 was lower than the U.S. statutory tax rate primarily due to the U.S. deduction for foreign derived intangible income, income earned by the Company’s international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate, federal and state tax credits, partially offset by U.S. tax on foreign earnings.

Non-Income Tax Matters

The Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates and records loss contingencies pursuant to ASC 450. Such amounts were not material for any of the periods presented. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.
v3.25.4
Intangible Assets and Goodwill
 3 Months Ended
Dec. 27, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible Assets
Intangible assets consisted of the following:
 
DescriptionAs of December 27, 2025As of September 27, 2025
Gross
Carrying
Value		Accumulated
Amortization		Gross
Carrying
Value		Accumulated
Amortization
Acquired intangible assets:
Developed technology$4,542.1 $4,058.0 $4,540.2 $4,015.8 
In-process research and development3.2 — 3.1 — 
Customer relationships594.5 580.0 593.7 578.1 
Trade names262.8 230.3 262.8 229.2 
Total acquired intangible assets$5,402.6 $4,868.3 $5,399.8 $4,823.1 
Internal-use software20.8 15.7 20.6 15.4 
Capitalized software embedded in products34.6 26.7 33.5 26.3 
Total intangible assets$5,458.0 $4,910.7 $5,453.9 $4,864.8 

The estimated remaining amortization expense of the Company’s acquired intangible assets as of December 27, 2025 for each of the five succeeding fiscal years was as follows:

Remainder of Fiscal 2026
$106.4 
Fiscal 2027$63.0 
Fiscal 2028$59.7 
Fiscal 2029
$53.4 
Fiscal 2030
$51.1 
v3.25.4
New Accounting Pronouncements
 3 Months Ended
Dec. 27, 2025
Accounting Policies [Abstract]  
New Accounting Pronouncements New Accounting Pronouncements
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures. The FASB issued this update to enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for fiscal years beginning after December 15, 2024 and is applicable to the Company for its annual report on Form 10-K for fiscal 2026. The adoption of ASU 2023-09 does not have an impact on the Company’s consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income (Topic 220) Expense Disaggregation Disclosures. This update is intended to improve the disclosures related to expenses and provide investors more detailed information about certain types of expenses. The updated guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2024-03 on its consolidated financial statements.

In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments - Credit Losses (Topic 326). This update introduces a practical expedient to address challenges encountered when applying guidance in Topic 326. The updated guidance is effective for fiscal years beginning after December 15, 2025, and interim periods within those annual reporting periods, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-05 on its consolidated financial statements.

In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40). The FASB issued this update to improve the accounting for software costs under Subtopic 350-40. The updated guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2029. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-06 on its consolidated financial statements.

In November 2025, the FASB issued ASU No. 2025-09, Derivatives and Hedging (Topic 815). The FASB issued this update to clarify the guidance for hedge accounting and address additional accounting issues related to the global reference rate reform initiative. The updated guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within those annual reporting periods, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-09 on its consolidated financial statements.
v3.25.4
Insider Trading Arrangements
 3 Months Ended
Dec. 27, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.4
Basis of Presentation (Policies)
 3 Months Ended
Dec. 27, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
The unaudited consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 27, 2025 included in the Company’s annual report on Form 10-K filed with the SEC on November 18, 2025. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
Principal of Consolidation
The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 27, 2025 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 26, 2026.
Proposed Merger
Proposed Merger

On October 21, 2025, the Company entered into a definitive agreement (“Merger Agreement”) to be acquired by funds managed by Blackstone Inc. (“Blackstone”) and TPG Capital (“TPG”) in a transaction valued at up to $79.00 per share. Under the terms of the agreement, Blackstone and TPG will acquire all outstanding Hologic shares for $76.00 per share in cash, without interest, plus a non-tradable contingent value right (“CVR”) to receive up to $3.00 per share in cash, for total potential consideration of up to $79.00 per share in cash. The non-tradable CVR will be issued to Hologic stockholders at closing and paid, in whole or in part, following achievement of certain global revenue metrics for Hologic’s Breast Health business in fiscal years 2026 and 2027.

The transaction is expected to close in the first half of calendar year 2026, subject to the approval of Hologic’s stockholders, the receipt of required regulatory approvals and the satisfaction of certain other customary closing conditions. Upon completion of the transaction, Hologic’s common stock will be delisted from the Nasdaq stock market and deregistered under the Securities Exchange Act of 1934, as amended.
Subsequent Events Consideration
Subsequent Events Consideration

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three months ended December 27, 2025.

On January 7, 2026, the Company executed a settlement agreement to resolve the BioZorb litigation with no admission of liability by the Company. The settlement amount is fully covered by insurance, and the Company expects it will bear no financial liability related to the settlement agreement. In addition, in connection with the potential merger with Blackstone and TPG and the Company filing a preliminary proxy statement on December 12, 2025 and a definitive proxy statement on December 23, 2025, on January 14, 2026 and January 15, 2026 purported stockholders of the Company filed a class action lawsuit and individual actions against the Company and the members of the Company’s board of directors. See footnote 10 for additional information.
New Accounting Pronouncements
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures. The FASB issued this update to enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for fiscal years beginning after December 15, 2024 and is applicable to the Company for its annual report on Form 10-K for fiscal 2026. The adoption of ASU 2023-09 does not have an impact on the Company’s consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income (Topic 220) Expense Disaggregation Disclosures. This update is intended to improve the disclosures related to expenses and provide investors more detailed information about certain types of expenses. The updated guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2024-03 on its consolidated financial statements.

In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments - Credit Losses (Topic 326). This update introduces a practical expedient to address challenges encountered when applying guidance in Topic 326. The updated guidance is effective for fiscal years beginning after December 15, 2025, and interim periods within those annual reporting periods, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-05 on its consolidated financial statements.

In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40). The FASB issued this update to improve the accounting for software costs under Subtopic 350-40. The updated guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2029. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-06 on its consolidated financial statements.

In November 2025, the FASB issued ASU No. 2025-09, Derivatives and Hedging (Topic 815). The FASB issued this update to clarify the guidance for hedge accounting and address additional accounting issues related to the global reference rate reform initiative. The updated guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within those annual reporting periods, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-09 on its consolidated financial statements.
v3.25.4
Revenue from Contract with Customer (Policies)
 3 Months Ended
Dec. 27, 2025
Revenue from Contract with Customer [Abstract]  
Revenue
(2) Revenue

The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customers (ASC 606), and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Company’s products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:    

Three Months Ended December 27, 2025
Business (in millions)
United StatesInternationalTotal
Diagnostics:
Cytology & Perinatal$76.0 $50.8 $126.8 
Molecular Diagnostics255.3 73.9 329.2 
Blood Screening8.4 — 8.4 
Total$339.7 $124.7 $464.4 
Breast Health:
Breast Imaging$219.9 $60.1 $280.0 
Interventional Breast Solutions71.2 24.7 95.9 
Total$291.1 $84.8 $375.9 
GYN Surgical$128.9 $51.9 $180.8 
Skeletal Health$13.8 $12.9 $26.7 
$773.5 $274.3 $1,047.8 

Three Months Ended December 28, 2024
Business (in millions)
United StatesInternationalTotal
Diagnostics:
Cytology & Perinatal$76.0 $49.4 $125.4 
Molecular Diagnostics262.6 78.5 341.1 
Blood Screening4.1 — 4.1 
Total$342.7 $127.9 $470.6 
Breast Health:
Breast Imaging$215.7 $65.9 $281.6 
Interventional Breast Solutions66.3 21.2 87.5 
Total$282.0 $87.1 $369.1 
GYN Surgical$121.9 $44.4 $166.3 
Skeletal Health$11.3 $4.5 $15.8 
$757.9 $263.9 $1,021.8 
Three Months Ended
Geographic Regions (in millions)
December 27, 2025December 28, 2024
United States$773.5 $757.9 
Europe161.6 148.9 
Asia-Pacific56.7 59.8 
Rest of World56.0 55.2 
$1,047.8 $1,021.8 

The following table provides revenue recognized by source:

Three Months Ended
Revenue by type (in millions)
December 27, 2025December 28, 2024
Disposables$644.2 $663.7 
Capital equipment, components and software187.2 154.2 
Service211.0 198.6 
Other5.4 5.3 
$1,047.8 $1,021.8 

The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts and extended warranty is recognized over time based on the period contracted and revenue from professional services for installation, training and repairs is recognized as the services are performed as these methods represent a faithful depiction of the transfer of goods and services.

The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized.

The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement.

Revenue from laboratory testing services, which is generated by the Company’s Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified.
Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts.

Variable Consideration

The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company’s contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. Estimates of variable consideration and constraints are not material to the Company’s financial statements.

Remaining Performance Obligations

As of December 27, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $841.6 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company’s Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 39% of this amount as revenue in fiscal 2026, 31% in fiscal 2027, 18% in fiscal 2028, 7% in fiscal 2029, and 5% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Contract Assets and Liabilities

The Company discloses accounts receivable separately in the Consolidated Balance Sheets at its net realizable value. Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company’s Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The Company recognized revenue of $73.1 million and $70.0 million in the three months ended December 27, 2025 and December 28, 2024, respectively, that was included in the contract liability at September 27, 2025 and September 28, 2024, respectively.

Practical Expedients

The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.
v3.25.4
Revenue (Tables)
 3 Months Ended
Dec. 27, 2025
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:    
Three Months Ended December 27, 2025
Business (in millions)
United StatesInternationalTotal
Diagnostics:
Cytology & Perinatal$76.0 $50.8 $126.8 
Molecular Diagnostics255.3 73.9 329.2 
Blood Screening8.4 — 8.4 
Total$339.7 $124.7 $464.4 
Breast Health:
Breast Imaging$219.9 $60.1 $280.0 
Interventional Breast Solutions71.2 24.7 95.9 
Total$291.1 $84.8 $375.9 
GYN Surgical$128.9 $51.9 $180.8 
Skeletal Health$13.8 $12.9 $26.7 
$773.5 $274.3 $1,047.8 

Three Months Ended December 28, 2024
Business (in millions)
United StatesInternationalTotal
Diagnostics:
Cytology & Perinatal$76.0 $49.4 $125.4 
Molecular Diagnostics262.6 78.5 341.1 
Blood Screening4.1 — 4.1 
Total$342.7 $127.9 $470.6 
Breast Health:
Breast Imaging$215.7 $65.9 $281.6 
Interventional Breast Solutions66.3 21.2 87.5 
Total$282.0 $87.1 $369.1 
GYN Surgical$121.9 $44.4 $166.3 
Skeletal Health$11.3 $4.5 $15.8 
$757.9 $263.9 $1,021.8 
Three Months Ended
Geographic Regions (in millions)
December 27, 2025December 28, 2024
United States$773.5 $757.9 
Europe161.6 148.9 
Asia-Pacific56.7 59.8 
Rest of World56.0 55.2 
$1,047.8 $1,021.8 

The following table provides revenue recognized by source:

Three Months Ended
Revenue by type (in millions)
December 27, 2025December 28, 2024
Disposables$644.2 $663.7 
Capital equipment, components and software187.2 154.2 
Service211.0 198.6 
Other5.4 5.3 
$1,047.8 $1,021.8 
v3.25.4
Fair Value Measurements (Tables)
 3 Months Ended
Dec. 27, 2025
Fair Value Disclosures [Abstract]  
Fair Value Assets and Liabilities Measured on Recurring Basis
The following table summarizes certain fair value information at December 27, 2025 and September 27, 2025 for investment assets and other liabilities measured at fair value on a recurring basis, as well as the carrying amount of certain investments.
  Fair Value at Reporting Date Using
 
Fair Value
Quoted Prices in
Active Market for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs (Level 2)		Significant
Unobservable
Inputs (Level 3)
December 27, 2025
Assets:
Money market mutual funds
$886.7 $886.7 $— $— 
U.S. Treasury securities
196.7 196.7 — — 
Interest rate swap
1.9 — 1.9 — 
Forward foreign currency contracts1.2 — 1.2 — 
Total$1,086.5 $1,083.4 $3.1 $— 
Liabilities:
Forward foreign currency contracts5.4 — 5.4 — 
Total$5.4 $— $5.4 $— 
September 27, 2025
Assets:
Money market mutual funds
$740.2 $740.2 $— $— 
U.S. Treasury securities
332.8 332.8 — — 
Interest rate swap
3.2 — 3.2 — 
Forward foreign currency contracts1.6 — 1.6 — 
Total$1,077.8 $1,073.0 $4.8 $— 
Liabilities:
Forward foreign currency contracts$6.1 $— $6.1 $— 
Total$6.1 $— $6.1 $— 
Schedule of Cash and Cash Equivalents
The Company’s cash and cash equivalents and short investments were as follows:

December 27, 2025
ValuationBalance Sheet Classification
in millionsCostUnrealized GainsUnrealized LossesFair ValueCash and cash equivalentsInvestments
Cash
$1,281.3 $— $— $1,281.3 $1,281.3 $— 
Money market mutual funds
886.7 — — 886.7 886.7 — 
U.S. Treasury debt securities
196.6 0.1 — 196.7 — 196.7 
Total
$2,364.6 $0.1 $— $2,364.7 $2,168.0 $196.7 
September 27, 2025
ValuationBalance Sheet Classification
in millionsCostUnrealized GainsUnrealized LossesFair ValueCash and cash equivalentsInvestments
Cash
$1,129.7 $— $— $1,129.7 $1,129.7 $— 
Money market mutual funds
740.2 — — 740.2 740.2 — 
U.S. Treasury debt securities
332.7 0.1 — 332.8 89.6 243.2 
Total
$2,202.6 $0.1 $— $2,202.7 $1,959.5 $243.2 
Debt Securities, Available-for-Sale
The fair value of the available-for-sale securities by contractual maturity as of December 27, 2025 and September 27, 2025 were as follows:

December 27, 2025September 27, 2025
in millions
Fair Value
Fair Value
Due in three months or less
$— $89.6 
Due after three months through one year
196.7 243.2 
Due after one year through five years
— — 
Total available-for-sale securities
$196.7 $332.8 
v3.25.4
Business Combinations (Tables)
 3 Months Ended
Dec. 27, 2025
Business Combination [Abstract]  
Business Combination, Recognized Asset Acquired and Liability Assumed
The purchase price was allocated to Gynesonics’ tangible and identifiable intangible assets and liabilities based on their estimated fair values as of January 2, 2025, as set forth below.
Cash$19.2 
Accounts receivable4.5 
Inventory7.2 
Other assets6.7 
Accounts payable and accrued expenses(21.1)
Identifiable intangible assets:
Developed technology140.8 
Trade names4.0 
Customer relationship1.3 
Deferred income taxes, net(14.1)
Goodwill192.2 
Purchase Price$340.7 
v3.25.4
Borrowings and Credit Arrangements (Tables)
 3 Months Ended
Dec. 27, 2025
Debt Disclosure [Abstract]  
Company's Borrowings
The Company’s borrowings consisted of the following: 

December 27,
2025		September 27,
2025
Current debt obligations, net of debt discount and deferred issuance costs:
Term Loan
$5.8 $2.9 
Total current debt obligations$5.8 $2.9 
Long-term debt obligations, net of debt discount and issuance costs:
Term Loan$1,161.0 $1,163.8 
2028 Senior Notes398.5 398.3 
2029 Senior Notes943.4 942.9 
Total long-term debt obligations$2,502.9 $2,505.0 
Total debt obligations$2,508.7 $2,507.9 
Schedule Of Interest Expense Under Credit Agreement
Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2025 Credit Agreement and the 2021 Credit Agreement were as follows: 
Three Months Ended
December 27, 2025December 28, 2024
Interest expense$15.8 $18.9 
Weighted average interest rate5.00 %5.66 %
Interest rate at end of period4.83 %5.44 %
Schedule of Interest Expense Under Convertible Notes
Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:

Three Months Ended
Interest RateDecember 27, 2025December 28, 2024
2028 Senior Notes4.625 %$4.8 $4.8 
2029 Senior Notes3.250 %8.2 8.2 
Total$13.0 $13.0 
v3.25.4
Trade Receivables and Allowance for Credit Losses (Tables)
 3 Months Ended
Dec. 27, 2025
Receivables [Abstract]  
Schedule of Accounts, Notes, Loans and Financing Receivable
The following is a rollforward of the allowance for credit losses as of December 27, 2025 compared to December 28, 2024:
Balance at
Beginning
of Period
Credit Loss (Gain)
Write-offs,
Payments and Foreign Exchange		Balance at
End of
Period
Three Months Ended:
December 27, 2025$38.2 $2.3 $(0.6)$39.9 
December 28, 2024$41.4 $(0.3)$(1.0)$40.1 
v3.25.4
Derivatives (Tables)
 3 Months Ended
Dec. 27, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments, Gain (Loss)
Three Months Ended
December 27, 2025December 28, 2024
Amount of realized gain (loss) recognized in income
Forward foreign currency contracts$(0.2)$0.3 
$(0.2)$0.3 
Amount of unrealized gain (loss) recognized in income
Forward foreign currency contracts$0.2 $22.4 
Foreign currency option contracts— (0.4)
$0.2 $22.0 
Amount of gain (loss) recognized in income
Total$— $22.3 
Schedule of Derivative Assets at Fair Value
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of December 27, 2025:

Balance Sheet LocationDecember 27, 2025September 27, 2025
Assets:
Derivative instruments designated as a cash flow hedge:
Interest rate swap contract
Prepaid expenses and other current assets$1.9 $3.2 
$1.9 $3.2 
Derivatives not designated as hedging instruments:
Forward foreign currency contractsPrepaid expenses and other current assets$1.2 $1.6 
$1.2 $1.6 
Liabilities:
Derivatives not designated as hedging instruments:
Forward foreign currency contractsAccrued expenses$5.4 $6.1 
Schedule of Unrealized Loss Recognized in AOCI
The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods:

Three Months Ended
December 27, 2025December 28, 2024
Amount of gain (loss) recognized in other comprehensive income, net of taxes:
Interest rate swap
$(1.0)$4.9 
Total$(1.0)$4.9 
v3.25.4
Net Income Per Share (Tables)
 3 Months Ended
Dec. 27, 2025
Earnings Per Share [Abstract]  
Reconciliation of Basic and Diluted Share Amounts
A reconciliation of basic and diluted share amounts is as follows:

 Three Months Ended
 December 27,
2025		December 28,
2024
Basic weighted average common shares outstanding224,405 230,284 
Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units1,474 1,823 
Diluted weighted average common shares outstanding225,879 232,107 
Weighted-average anti-dilutive shares related to:
Outstanding stock options and restricted stock units1,449 829 
v3.25.4
Stock-Based Compensation (Tables)
 3 Months Ended
Dec. 27, 2025
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Expense in Consolidated Statements of Operations
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income:

 Three Months Ended
 December 27,
2025		December 28,
2024
Cost of revenues$3.7 $3.5 
Research and development1.8 2.5 
Selling and marketing4.1 3.7 
General and administrative17.3 20.4 
$26.9 $30.1 
Weighted-Average Assumptions Utilized to Value Stock Options
The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:

 Three Months Ended
 
December 27,
2025 (1)
December 28,
2024
Risk-free interest rate— %4.2 %
Expected volatility— %32.5 %
Expected life (in years)— 4.8
Dividend yield— — 
Weighted average fair value of options granted$— $26.74 
(1) No stock option awards were granted in the first quarter of fiscal 2026
v3.25.4
Other Balance Sheet Information (Tables)
 3 Months Ended
Dec. 27, 2025
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Information of Inventories
December 27,
2025		September 27,
2025
Inventories
Raw materials$282.0 $247.8 
Work-in-process62.9 68.4 
Finished goods343.6 363.2 
$688.5 $679.4 
Other Balance Sheet Information of Property, Plant and Equipment
Property, plant and equipment
Equipment$391.1 $383.8 
Equipment under customer usage agreements596.5 586.8 
Building and improvements261.1 256.1 
Leasehold improvements49.4 49.1 
Land40.9 40.9 
Furniture and fixtures26.4 26.5 
Finance lease right-of-use asset
9.2 9.2 
$1,374.6 $1,352.4 
Less – accumulated depreciation and amortization(806.3)(792.8)
$568.3 $559.6 
v3.25.4
Business Segments and Geographic Information (Tables)
 3 Months Ended
Dec. 27, 2025
Segment Reporting [Abstract]  
Segment Information
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company has presented all other identifiable assets as corporate assets.

Three Months Ended December 27, 2025
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthConsolidated
Total revenues$464.4 $375.9 $180.8 $26.7 $1,047.8 
Segment expenses:
Cost of revenues173.9 157.3 67.6 18.8 417.6 
Research and development26.8 24.0 8.4 0.6 59.8 
Sales and marketing56.5 51.1 44.4 1.9 153.9 
General and administrative49.7 40.7 19.9 2.6 112.9 
Segment income from operations$157.5 $102.8 $40.5 $2.8 $303.6 
Unallocated amounts:
Cost of revenue adjustments(1)
2.7 
Amortization of acquired intangible assets43.3 
Restructuring, integration, acquisition-related charges and legal settlements20.6 
Income from operations$237.0 
Interest expense, net(7.9)
Foreign currency and other non-operating income, net0.6 
Income before income taxes$229.7 
(1) Primarily related to costs associated with the shutdown of the Manchester, England manufacturing location, primarily manufacturing period costs and retention benefits related to the merger.
Three Months Ended December 27, 2025
DiagnosticsBreast HealthGYN SurgicalSkeletal Health
Corporate
Consolidated
Depreciation and amortization
$46.2 $12.9 $10.3 $0.2 $— $69.6 
Capital expenditures
23.7 5.6 4.9 — 0.9 35.1 
Identifiable assets
2,232.6 1,526.7 1,636.8 37.7 3,746.9 9,180.7 
Three Months Ended December 28, 2024
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthConsolidated
Total revenues$470.6 $369.1 $166.3 $15.8 $1,021.8 
Segment expenses:
Cost of revenues173.8 160.3 44.8 13.1 392.0 
Research and development32.1 21.0 6.5 0.6 60.2 
Sales and marketing59.6 54.8 39.4 3.0 156.8 
General and administrative49.6 43.3 17.0 2.2 112.1 
Segment income (loss) from operations$155.5 $89.7 $58.6 $(3.1)$300.7 
Unallocated amounts:
Cost of revenue adjustments(1)
3.2 
Amortization of acquired intangible assets50.7 
Restructuring, integration and acquisition-related charges17.0 
Income from operations$229.8 
Interest expense, net(6.3)
Foreign currency and other non-operating income, net24.0 
Income before income taxes$247.5 
(1) Related to the fair value write-up of inventory sold related to the Endomagnetics acquisition.
Three Months Ended December 28, 2024
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthCorporateConsolidated
Depreciation and amortization
$48.6 $13.2 $12.0 $0.2 $— $74.0 
Capital expenditures
17.8 8.9 3.7 — 1.2 31.6 
Year Ended September 27, 2025
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthCorporateConsolidated
Identifiable assets
$2,244.0 $1,531.3 $1,644.9 $31.2 $3,563.5 $9,014.9 
Revenues by Geography
Revenues by geography as a percentage of total revenues were as follows:
 
 Three Months Ended
 December 27,
2025		December 28,
2024
United States73.8 %74.2 %
Europe15.4 %14.6 %
Asia-Pacific5.4 %5.9 %
Rest of World5.4 %5.3 %
100.0 %100.0 %
v3.25.4
Intangible Assets and Goodwill (Tables)
 3 Months Ended
Dec. 27, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Intangible assets consisted of the following:
 
DescriptionAs of December 27, 2025As of September 27, 2025
Gross
Carrying
Value		Accumulated
Amortization		Gross
Carrying
Value		Accumulated
Amortization
Acquired intangible assets:
Developed technology$4,542.1 $4,058.0 $4,540.2 $4,015.8 
In-process research and development3.2 — 3.1 — 
Customer relationships594.5 580.0 593.7 578.1 
Trade names262.8 230.3 262.8 229.2 
Total acquired intangible assets$5,402.6 $4,868.3 $5,399.8 $4,823.1 
Internal-use software20.8 15.7 20.6 15.4 
Capitalized software embedded in products34.6 26.7 33.5 26.3 
Total intangible assets$5,458.0 $4,910.7 $5,453.9 $4,864.8 
Schedule of Estimated Amortization Expense
The estimated remaining amortization expense of the Company’s acquired intangible assets as of December 27, 2025 for each of the five succeeding fiscal years was as follows:

Remainder of Fiscal 2026
$106.4 
Fiscal 2027$63.0 
Fiscal 2028$59.7 
Fiscal 2029
$53.4 
Fiscal 2030
$51.1 
v3.25.4
Basis of Presentation (Details) - Blackstone Inc. (“Blackstone”) and TPG Capital (“TPG”) - Merger Agreement
Oct. 21, 2025
$ / shares
Without Interest  
Business Combination [Line Items]  
Price per share (in dollars per share) $ 76.00
Maximum  
Business Combination [Line Items]  
Price per share (in dollars per share) 79.00
Maximum | Plus a Non-Tradable Contingent Value Right  
Business Combination [Line Items]  
Price per share (in dollars per share) $ 3.00
v3.25.4
Revenue - Business Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Disaggregation of Revenue [Line Items]    
Revenues $ 1,047.8 $ 1,021.8
United States    
Disaggregation of Revenue [Line Items]    
Revenues 773.5 757.9
International    
Disaggregation of Revenue [Line Items]    
Revenues 274.3 263.9
Diagnostics    
Disaggregation of Revenue [Line Items]    
Revenues 464.4 470.6
Diagnostics | United States    
Disaggregation of Revenue [Line Items]    
Revenues 339.7 342.7
Diagnostics | International    
Disaggregation of Revenue [Line Items]    
Revenues 124.7 127.9
Diagnostics | Cytology & Perinatal    
Disaggregation of Revenue [Line Items]    
Revenues 126.8 125.4
Diagnostics | Cytology & Perinatal | United States    
Disaggregation of Revenue [Line Items]    
Revenues 76.0 76.0
Diagnostics | Cytology & Perinatal | International    
Disaggregation of Revenue [Line Items]    
Revenues 50.8 49.4
Diagnostics | Molecular Diagnostics    
Disaggregation of Revenue [Line Items]    
Revenues 329.2 341.1
Diagnostics | Molecular Diagnostics | United States    
Disaggregation of Revenue [Line Items]    
Revenues 255.3 262.6
Diagnostics | Molecular Diagnostics | International    
Disaggregation of Revenue [Line Items]    
Revenues 73.9 78.5
Diagnostics | Blood Screening    
Disaggregation of Revenue [Line Items]    
Revenues 8.4 4.1
Diagnostics | Blood Screening | United States    
Disaggregation of Revenue [Line Items]    
Revenues 8.4 4.1
Diagnostics | Blood Screening | International    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 0.0
Breast Health    
Disaggregation of Revenue [Line Items]    
Revenues 375.9 369.1
Breast Health | United States    
Disaggregation of Revenue [Line Items]    
Revenues 291.1 282.0
Breast Health | International    
Disaggregation of Revenue [Line Items]    
Revenues 84.8 87.1
Breast Health | Breast Imaging    
Disaggregation of Revenue [Line Items]    
Revenues 280.0 281.6
Breast Health | Breast Imaging | United States    
Disaggregation of Revenue [Line Items]    
Revenues 219.9 215.7
Breast Health | Breast Imaging | International    
Disaggregation of Revenue [Line Items]    
Revenues 60.1 65.9
Breast Health | Interventional Breast Solutions    
Disaggregation of Revenue [Line Items]    
Revenues 95.9 87.5
Breast Health | Interventional Breast Solutions | United States    
Disaggregation of Revenue [Line Items]    
Revenues 71.2 66.3
Breast Health | Interventional Breast Solutions | International    
Disaggregation of Revenue [Line Items]    
Revenues 24.7 21.2
GYN Surgical    
Disaggregation of Revenue [Line Items]    
Revenues 180.8 166.3
GYN Surgical | United States    
Disaggregation of Revenue [Line Items]    
Revenues 128.9 121.9
GYN Surgical | International    
Disaggregation of Revenue [Line Items]    
Revenues 51.9 44.4
Skeletal Health    
Disaggregation of Revenue [Line Items]    
Revenues 26.7 15.8
Skeletal Health | United States    
Disaggregation of Revenue [Line Items]    
Revenues 13.8 11.3
Skeletal Health | International    
Disaggregation of Revenue [Line Items]    
Revenues $ 12.9 $ 4.5
v3.25.4
Revenue - Geographical Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Disaggregation of Revenue [Line Items]    
Revenues $ 1,047.8 $ 1,021.8
United States    
Disaggregation of Revenue [Line Items]    
Revenues 773.5 757.9
Europe    
Disaggregation of Revenue [Line Items]    
Revenues 161.6 148.9
Asia-Pacific    
Disaggregation of Revenue [Line Items]    
Revenues 56.7 59.8
Rest of World    
Disaggregation of Revenue [Line Items]    
Revenues $ 56.0 $ 55.2
v3.25.4
Revenue - Revenue by Type (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Disaggregation of Revenue [Line Items]    
Revenues $ 1,047.8 $ 1,021.8
Disposables    
Disaggregation of Revenue [Line Items]    
Revenues 644.2 663.7
Capital equipment, components and software    
Disaggregation of Revenue [Line Items]    
Revenues 187.2 154.2
Service    
Disaggregation of Revenue [Line Items]    
Revenues 211.0 198.6
Other    
Disaggregation of Revenue [Line Items]    
Revenues $ 5.4 $ 5.3
v3.25.4
Revenue - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Revenue from Contract with Customer [Abstract]    
Revenue, Remaining Performance Obligation, Amount $ 841.6  
Contract with Customer, Liability, Revenue Recognized $ 73.1 $ 70.0
v3.25.4
Revenue - Remaining Performance Obligation (Details)
Dec. 27, 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-12-28  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 39.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-09-28  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 31.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-09-28  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 18.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-09-28  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 7.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2030-09-28  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 5.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
v3.25.4
Leases - Additional Lease Information (Details)
 3 Months Ended
Dec. 27, 2025
Leases [Abstract]  
Lease revenue as a percentage of total (percentage) 0.03
v3.25.4
Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Assets:    
Total available-for-sale securities $ 196.7 $ 332.8
Total 1,086.5 1,077.8
Liabilities:    
Total 5.4 6.1
Quoted Prices in Active Market for Identical Assets (Level 1)    
Assets:    
Total 1,083.4 1,073.0
Liabilities:    
Total 0.0 0.0
Significant Other Observable Inputs (Level 2)    
Assets:    
Total 3.1 4.8
Liabilities:    
Total 5.4 6.1
Significant Unobservable Inputs (Level 3)    
Assets:    
Total 0.0 0.0
Liabilities:    
Total 0.0 0.0
Interest rate swap    
Assets:    
Interest rate swap 1.9 3.2
Interest rate swap | Quoted Prices in Active Market for Identical Assets (Level 1)    
Assets:    
Interest rate swap 0.0 0.0
Interest rate swap | Significant Other Observable Inputs (Level 2)    
Assets:    
Interest rate swap 1.9 3.2
Interest rate swap | Significant Unobservable Inputs (Level 3)    
Assets:    
Interest rate swap 0.0 0.0
Forward foreign currency contracts    
Assets:    
Forward foreign currency contracts 1.2 1.6
Liabilities:    
Forward foreign currency contracts 5.4 6.1
Forward foreign currency contracts | Quoted Prices in Active Market for Identical Assets (Level 1)    
Assets:    
Forward foreign currency contracts 0.0 0.0
Liabilities:    
Forward foreign currency contracts 0.0 0.0
Forward foreign currency contracts | Significant Other Observable Inputs (Level 2)    
Assets:    
Forward foreign currency contracts 1.2 1.6
Liabilities:    
Forward foreign currency contracts 5.4 6.1
Forward foreign currency contracts | Significant Unobservable Inputs (Level 3)    
Assets:    
Forward foreign currency contracts 0.0 0.0
Liabilities:    
Forward foreign currency contracts 0.0 0.0
Money Market Funds    
Assets:    
Money market mutual funds 886.7 740.2
Money Market Funds | Quoted Prices in Active Market for Identical Assets (Level 1)    
Assets:    
Money market mutual funds 886.7 740.2
Money Market Funds | Significant Other Observable Inputs (Level 2)    
Assets:    
Money market mutual funds 0.0 0.0
Money Market Funds | Significant Unobservable Inputs (Level 3)    
Assets:    
Money market mutual funds 0.0 0.0
US Treasury Securities    
Assets:    
Total available-for-sale securities 196.7 332.8
US Treasury Securities | Quoted Prices in Active Market for Identical Assets (Level 1)    
Assets:    
Total available-for-sale securities 196.7 332.8
US Treasury Securities | Significant Other Observable Inputs (Level 2)    
Assets:    
Total available-for-sale securities 0.0 0.0
US Treasury Securities | Significant Unobservable Inputs (Level 3)    
Assets:    
Total available-for-sale securities $ 0.0 $ 0.0
v3.25.4
Fair Value Measurements - Additional Information (Detail)
$ in Millions
Dec. 27, 2025
USD ($)
2028 Senior Notes  
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]  
Fair value of debt instrument $ 400.0
2029 Senior Notes  
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]  
Fair value of debt instrument 938.7
Credit Agreement  
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]  
Borrowed principal $ 1,170.0
2028 Senior Notes | Senior Notes  
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]  
Stated interest rate 4.625%
2029 Senior Notes | Senior Notes  
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]  
Stated interest rate 3.25%
v3.25.4
Fair Value Measurements - Cash and Cash Equivalents (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 27, 2025
Sep. 27, 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cost $ 2,168.0 $ 1,959.5
Short-Term Investments, Unrealized Gain 0.1 0.1
Short-Term Investments, Unrealized Loss 0.0 0.0
Total available-for-sale securities 196.7 332.8
Cash, Cash Equivalents, and Short-Term Investments 2,364.6 2,202.6
Cash, Cash Equivalents, and Short-Term Investments, Fair Value 2,364.7 2,202.7
Investments 196.7 243.2
Cash    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cost 1,281.3 1,129.7
Unrealized Gains 0.0 0.0
Unrealized Losses 0.0 0.0
Fair Value 1,281.3 1,129.7
Money Market Funds    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cost 886.7 740.2
Unrealized Gains 0.0 0.0
Unrealized Losses 0.0 0.0
Fair Value 886.7 740.2
Investments 0.0 0.0
US Treasury Securities    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cost 0.0 89.6
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss 196.6 332.7
Investments, Unrealized Gain 0.1 0.1
Investments, Unrealized Loss 0.0 0.0
Total available-for-sale securities 196.7 332.8
Investments $ 196.7 $ 243.2
v3.25.4
Fair Value Measurements - Available for Sale Debt Securities (Details) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Fair Value Disclosures [Abstract]    
Due in three months or less $ 0.0 $ 89.6
Due after three months through one year 196.7 243.2
Due after one year through five years 0.0 0.0
Total available-for-sale securities $ 196.7 $ 332.8
v3.25.4
Business Combinations - Additional Information (Details) - Gynesonics, Inc. - USD ($)
 3 Months Ended
Jan. 02, 2025
Dec. 27, 2025
Mar. 29, 2025
Business Combination [Line Items]      
Consideration transferred $ 340,700,000    
Accelerated cost     $ 22,400,000
Increase in deferred income taxes   $ 1,200,000  
Measurement input 12.00%    
Goodwill, expected tax deductible amount $ 0    
Developed technology      
Business Combination [Line Items]      
Intangible assets useful life 13 years    
Trade Names      
Business Combination [Line Items]      
Intangible assets useful life 13 years    
Customer Relationships      
Business Combination [Line Items]      
Intangible assets useful life 13 years    
Cost Of Goods And Services Sold      
Business Combination [Line Items]      
Accelerated cost     1,600,000
Operating Expense      
Business Combination [Line Items]      
Accelerated cost     $ 20,800,000
v3.25.4
Business Combinations - Purchase Price Allocation (Details) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Jan. 02, 2025
Business Combination [Line Items]      
Goodwill $ 3,645.2 $ 3,640.6  
Gynesonics, Inc.      
Business Combination [Line Items]      
Cash     $ 19.2
Accounts receivable     4.5
Inventory     7.2
Other assets     6.7
Accounts payable and accrued expenses     (21.1)
Deferred income taxes, net     (14.1)
Goodwill     192.2
Purchase Price     340.7
Gynesonics, Inc. | Developed technology      
Business Combination [Line Items]      
Identifiable intangible assets:     140.8
Gynesonics, Inc. | Trade Names      
Business Combination [Line Items]      
Identifiable intangible assets:     4.0
Gynesonics, Inc. | Customer Relationships      
Business Combination [Line Items]      
Identifiable intangible assets:     $ 1.3
v3.25.4
Strategic Investments (Details) - USD ($)
 3 Months Ended
Nov. 13, 2023
Dec. 27, 2025
Dec. 28, 2024
Sep. 27, 2025
Schedule of Equity Method Investments [Line Items]        
Impairment loss   $ 0 $ 0  
Equity securities without readily determinable fair value   68,100,000   $ 53,100,000
Maverix Medical LLC        
Schedule of Equity Method Investments [Line Items]        
Payments to acquire equity method investments $ 24,500,000      
Ownership percentage 45.00%      
Equity method investments   27,200,000    
Loss from equity method investments   $ 2,800,000 $ 1,500,000  
Capital call notice, percent of committed capital   13.30% 13.30%  
Committed capital   $ 9,000,000 $ 9,000,000  
v3.25.4
Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Debt Instrument [Line Items]    
Current portion of long-term debt $ 5.8 $ 2.9
Total long-term debt obligations 2,502.9 2,505.0
Total debt obligations 2,508.7 2,507.9
Term Loan    
Debt Instrument [Line Items]    
Current portion of long-term debt 5.8 2.9
Long term debt obligations. excluding convertible notes 1,161.0 1,163.8
2028 Senior Notes    
Debt Instrument [Line Items]    
Long term debt obligations. excluding convertible notes 398.5 398.3
2029 Senior Notes    
Debt Instrument [Line Items]    
Long term debt obligations. excluding convertible notes $ 943.4 $ 942.9
v3.25.4
Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Jul. 15, 2025
Interest rate swap      
Debt Instrument [Line Items]      
Proceeds from swap $ 1.3 $ 1.6  
Credit Agreement      
Debt Instrument [Line Items]      
Interest rate at end of period 4.83% 5.44%  
Secured Term Loan | 2025 Term Loan      
Debt Instrument [Line Items]      
Senior notes, face amount     $ 1,169.0
Revolver | 2025 Revolver      
Debt Instrument [Line Items]      
Revolving credit facility borrowings     $ 1,250.0
Senior Notes | 2028 Senior Notes      
Debt Instrument [Line Items]      
Stated interest rate 4.625%    
Senior notes $ 400.0    
Senior Notes | 2029 Senior Notes      
Debt Instrument [Line Items]      
Stated interest rate 3.25%    
Senior notes $ 950.0    
v3.25.4
Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - Credit Agreement - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Line of Credit Facility [Line Items]    
Interest expense $ 15.8 $ 18.9
Weighted average interest rate 5.00% 5.66%
Interest rate at end of period 4.83% 5.44%
v3.25.4
Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - Senior Notes - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
2028 Senior Notes    
Line of Credit Facility [Line Items]    
Stated interest rate 4.625%  
Interest expense $ 4.8 $ 4.8
2029 Senior Notes    
Line of Credit Facility [Line Items]    
Stated interest rate 3.25%  
Interest expense $ 8.2 8.2
Total    
Line of Credit Facility [Line Items]    
Interest expense $ 13.0 $ 13.0
v3.25.4
Trade Receivables and Allowance for Credit Losses (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Balance at Beginning of Period $ 38.2 $ 41.4
Credit Loss (Gain) 2.3 (0.3)
Write-offs, Payments and Foreign Exchange (0.6) (1.0)
Balance at End of Period $ 39.9 $ 40.1
v3.25.4
Derivatives - Additional Information (Details) - USD ($)
$ in Millions
Dec. 27, 2025
Mar. 23, 2023
Interest Rate Swap, 2023    
Derivative [Line Items]    
Derivative notional amount   $ 500.0
Variable interest rate   3.46%
Interest Rate Swap, 2024    
Derivative [Line Items]    
Derivative notional amount   $ 500.0
Variable interest rate   2.98%
Cash Flow Hedge Derivative Instrument Assets at Fair Value $ 1.9  
Forward and option contracts    
Derivative [Line Items]    
Derivative notional amount $ 251.3  
v3.25.4
Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Derivative Instruments, Gain (Loss) [Line Items]    
Total $ 0.0 $ 22.3
Derivatives not designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of realized gain (loss) recognized in income (0.2) 0.3
Amount of unrealized gain (loss) recognized in income 0.2 22.0
Forward foreign currency contracts | Derivatives not designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of realized gain (loss) recognized in income (0.2) 0.3
Amount of unrealized gain (loss) recognized in income 0.2 22.4
Foreign currency option contracts | Derivatives not designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of unrealized gain (loss) recognized in income $ 0.0 $ (0.4)
v3.25.4
Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Derivative instruments designated as a cash flow hedge | Interest rate swaps    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative Asset, Subject to Master Netting Arrangement, before Offset $ 1.9 $ 3.2
Derivative instruments designated as a cash flow hedge | Interest rate swaps | Prepaid expenses and other current assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value 1.9 3.2
Derivatives not designated as hedging instruments    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative Asset, Subject to Master Netting Arrangement, before Offset 1.2 1.6
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value 1.2 1.6
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash Flow Hedge Derivative Instrument Assets at Fair Value $ 5.4 $ 6.1
v3.25.4
Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in other comprehensive income, net of taxes: $ (1.0) $ 4.9
Interest rate swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in other comprehensive income, net of taxes: $ (1.0) $ 4.9
v3.25.4
Commitments and Contingencies (Details)
Nov. 04, 2022
claim
plaintiff
Loss Contingencies [Line Items]  
Number of plaintiffs | plaintiff 200
Massachusetts  
Loss Contingencies [Line Items]  
Pending claims, number | claim 1
v3.25.4
Net Income Per Share (Detail) - shares
shares in Thousands
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Earnings Per Share [Line Items]    
Basic weighted average common shares outstanding 224,405 230,284
Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,474 1,823
Diluted weighted average common shares outstanding 225,879 232,107
Outstanding Stock Options and stock units    
Weighted-average anti-dilutive shares related to:    
Weighted-average anti-dilutive shares (in shares) 1,449 829
v3.25.4
Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expense $ 26.9 $ 30.1
Cost of revenues    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expense 3.7 3.5
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expense 1.8 2.5
Selling and marketing    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expense 4.1 3.7
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expense $ 17.3 $ 20.4
v3.25.4
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted (in shares) 0  
Stock option plans    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted (in shares) 0 500,000
Weighted-average exercise prices (in dollars per share)   $ 79.38
Share-based compensation, stock options outstanding (in shares) 4,200,000  
Weighted-average exercise price of options outstanding (in dollars per share) $ 58.31  
Unrecognized compensation expense $ 8.0  
Weighted-average period for recognition of unrecognized stock-based compensation, years 2 years 3 months 18 days  
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares) 1,100,000 800,000
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share) $ 74.28 $ 79.88
Unrecognized compensation expense $ 98.6  
Weighted-average period for recognition of unrecognized stock-based compensation, years 2 years  
Performance Shares    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares)   100,000
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)   $ 79.39
PSU Free Cash Flow    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares)   100,000
Period 3 years  
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)   $ 79.39
Minimum eligible percentage to receive target number of shares of company's common stock 0.00%  
Maximum eligible percentage to receive target number of shares of company's common stock 200.00%  
Performance stock units vesting period 3 years  
Market Based Awards    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares)   100,000
Period 3 years  
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)   $ 87.41
Minimum eligible percentage to receive target number of shares of company's common stock 0.00%  
Maximum eligible percentage to receive target number of shares of company's common stock 200.00%  
Performance stock units vesting period 3 years  
RSU, PSU, MSU    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) 2,100,000  
v3.25.4
Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]    
Risk-free interest rate 0.00% 4.20%
Expected volatility 0.00% 32.50%
Expected life (in years)   4 years 9 months 18 days
Dividend yield $ 0 $ 0
Weighted average fair value of options granted $ 0 $ 26.74
Options granted (in shares) 0  
v3.25.4
Other Balance Sheet Information - Inventories (Detail) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Balance Sheet Related Disclosures [Abstract]    
Raw materials $ 282.0 $ 247.8
Work-in-process 62.9 68.4
Finished goods 343.6 363.2
Inventories $ 688.5 $ 679.4
v3.25.4
Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Balance Sheet Related Disclosures [Abstract]    
Equipment $ 391.1 $ 383.8
Equipment under customer usage agreements 596.5 586.8
Building and improvements 261.1 256.1
Leasehold improvements 49.4 49.1
Land 40.9 40.9
Furniture and fixtures 26.4 26.5
Finance Lease, Right-of-Use Asset, after Accumulated Amortization 9.2 9.2
Property, plant and equipment, gross 1,374.6 1,352.4
Less – accumulated depreciation and amortization (806.3) (792.8)
Property, plant and equipment, net $ 568.3 $ 559.6
v3.25.4
Business Segments and Geographic Information - Additional Information (Detail)
$ in Millions
 3 Months Ended
Dec. 27, 2025
USD ($)
project
Dec. 28, 2024
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | project 4  
Revenues | $ $ 1,047.8 $ 1,021.8
v3.25.4
Business Segments and Geographic Information - Segment Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Sep. 27, 2025
Segment Reporting Information [Line Items]      
Total revenues $ 1,047.8 $ 1,021.8  
Cost of revenue 417.6 392.0  
Research and development 59.8 60.2  
Sales and marketing 153.9 156.8  
General and administrative 112.9 112.1  
Income (loss) from operations 237.0 229.8  
Cost of revenue adjustments 2.7 3.2  
Amortization of acquired intangible assets 43.3 50.7  
Restructuring, integration, acquisition-related charges and legal settlements 20.6 17.0  
Interest expense, net (7.9) (6.3)  
Foreign currency and other non-operating income, net 0.6 24.0  
Income before income taxes 229.7 247.5  
Depreciation and amortization 69.6 74.0  
Capital expenditures 35.1 31.6  
Identifiable assets 9,180.7   $ 9,014.9
Diagnostics      
Segment Reporting Information [Line Items]      
Total revenues 464.4 470.6  
Breast Health      
Segment Reporting Information [Line Items]      
Total revenues 375.9 369.1  
GYN Surgical      
Segment Reporting Information [Line Items]      
Total revenues 180.8 166.3  
Skeletal Health      
Segment Reporting Information [Line Items]      
Total revenues 26.7 15.8  
Operating Segments      
Segment Reporting Information [Line Items]      
Income (loss) from operations 303.6 300.7  
Operating Segments | Diagnostics      
Segment Reporting Information [Line Items]      
Total revenues 464.4 470.6  
Cost of revenue 173.9 173.8  
Research and development 26.8 32.1  
Sales and marketing 56.5 59.6  
General and administrative 49.7 49.6  
Income (loss) from operations 157.5 155.5  
Depreciation and amortization 46.2 48.6  
Capital expenditures 23.7 17.8  
Identifiable assets 2,232.6   2,244.0
Operating Segments | Breast Health      
Segment Reporting Information [Line Items]      
Total revenues 375.9 369.1  
Cost of revenue 157.3 160.3  
Research and development 24.0 21.0  
Sales and marketing 51.1 54.8  
General and administrative 40.7 43.3  
Income (loss) from operations 102.8 89.7  
Depreciation and amortization 12.9 13.2  
Capital expenditures 5.6 8.9  
Identifiable assets 1,526.7   1,531.3
Operating Segments | GYN Surgical      
Segment Reporting Information [Line Items]      
Total revenues 180.8 166.3  
Cost of revenue 67.6 44.8  
Research and development 8.4 6.5  
Sales and marketing 44.4 39.4  
General and administrative 19.9 17.0  
Income (loss) from operations 40.5 58.6  
Depreciation and amortization 10.3 12.0  
Capital expenditures 4.9 3.7  
Identifiable assets 1,636.8   1,644.9
Operating Segments | Skeletal Health      
Segment Reporting Information [Line Items]      
Total revenues 26.7 15.8  
Cost of revenue 18.8 13.1  
Research and development 0.6 0.6  
Sales and marketing 1.9 3.0  
General and administrative 2.6 2.2  
Income (loss) from operations 2.8 (3.1)  
Depreciation and amortization 0.2 0.2  
Capital expenditures 0.0 0.0  
Identifiable assets 37.7   31.2
Corporate | Skeletal Health      
Segment Reporting Information [Line Items]      
Depreciation and amortization 0.0 0.0  
Capital expenditures 0.9 $ 1.2  
Identifiable assets $ 3,746.9   $ 3,563.5
v3.25.4
Business Segments and Geographic Information - Revenues by Geography (Detail)
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Schedule Of Geographical Segments [Line Items]    
Revenues 100.00% 100.00%
United States    
Schedule Of Geographical Segments [Line Items]    
Revenues 73.80% 74.20%
Europe    
Schedule Of Geographical Segments [Line Items]    
Revenues 15.40% 14.60%
Asia-Pacific    
Schedule Of Geographical Segments [Line Items]    
Revenues 5.40% 5.90%
Rest of World    
Schedule Of Geographical Segments [Line Items]    
Revenues 5.40% 5.30%
v3.25.4
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 27, 2025
Dec. 28, 2024
Income Tax Disclosure [Abstract]    
Income tax expense (benefit) $ 50.6 $ 46.5
Company's effective tax rate 22.00% 18.80%
v3.25.4
Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($)
$ in Millions
Dec. 27, 2025
Sep. 27, 2025
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 5,458.0 $ 5,453.9
Accumulated Amortization 4,910.7 4,864.8
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 4,542.1 4,540.2
Accumulated Amortization 4,058.0 4,015.8
In-process research and development    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 3.2 3.1
Accumulated Amortization 0.0 0.0
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 594.5 593.7
Accumulated Amortization 580.0 578.1
Trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 262.8 262.8
Accumulated Amortization 230.3 229.2
Total acquired intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 5,402.6 5,399.8
Accumulated Amortization 4,868.3 4,823.1
Internal-use software    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 20.8 20.6
Accumulated Amortization 15.7 15.4
Capitalized software embedded in products    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 34.6 33.5
Accumulated Amortization $ 26.7 $ 26.3
v3.25.4
Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail)
$ in Millions
Dec. 27, 2025
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Remainder of Fiscal 2026 $ 106.4
Fiscal 2027 63.0
Fiscal 2028 59.7
Fiscal 2029 53.4
Fiscal 2030 $ 51.1